

MINOLIRA - (EQ 105MG BASE, EQ 135MG BASE ; TABLET,EXTENDED RELEASE)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | MINOCYCLINE HYDROCHLORIDE | Innovator | EPI HLTH |
| Dosage | EQ 105MG BASE, EQ 135MG BASE ; TABLET,EXTENDED RELEASE | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | None |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | MINOLIRA is a tetracycline-class drug indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.